Ciclopirox ethanolamine |
Catalog No.GC11120
One-Click Copy Product Info
|
시클로피록스 에탄올아민(Ciclopirox ethanolamine)은 표재성 진균증 재발에 사용할 수 있는 합성 항진균제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 41621-49-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ciclopirox ethanolamine is a synthetic broad-spectrum antifungal agent belonging to the hydroxypyridone derivative class, exhibiting antifungal, antibacterial, and anti-inflammatory activities. Ciclopirox ethanolamine functions as an iron chelator that chelates polyvalent cations, inhibits metal-dependent enzymes, interferes with mitochondrial transport processes, and affects cell membrane permeability. Ciclopirox ethanolamine shows potential application value in research areas including antitumor therapy, stem cell and developmental biology, neurodegenerative diseases, and autoimmune diseases[1-4].
In vitro, treatment with 0.064-40μM Ciclopirox ethanolamine for 48 hours reduced cell viability, induced apoptosis, and decreased mitochondrial membrane potential in K562, HL-60, Jurkat, RS4-11, OCI-M2, and OCI-AML2 cells[5]. Pretreatment with 0.2-2μM Ciclopirox ethanolamine for 2 hours followed by 8-hour oxygen-glucose deprivation and 24-hour reoxygenation increased cell viability, reduced apoptotic cell proportion, and attenuated cell shrinkage in 661W photoreceptor cells[6]. Treatment with 0-20μM Ciclopirox ethanolamine for 24 hours decreased p-S6K1 and p-4E-BP1 levels and reduced cell numbers in Rh30, RD, MDA-MB-231, MDA-MB-435, PC-3, PCI-13, and SRB1-M7 cells[7].
In vivo, intraperitoneal injection of 10mg/kg Ciclopirox ethanolamine once daily for 27 consecutive days reduced kidney-to-body weight ratio, kidney size, cystic index, blood urea nitrogen levels, Ki67-positive cell proportion in renal tissue, fibrosis degree, and ferritin (FTH1/FTL) protein levels, while increasing LC3B-II and NCOA4 protein levels in renal tissue of Pkd1RC/RC Pkd2+/- polycystic kidney disease (PKD) mice[8]. A single intraperitoneal injection of 10-20mg/kg Ciclopirox ethanolamine improved survival rate, reduced serum ALT and AST levels, ameliorated liver pathological injury, decreased serum and liver IL-1β levels, and attenuated caspase-1 cleavage and IL-1β maturation in liver tissue of LPS-induced septic C57BL/6 mice[9]. Topical application of 1-3μg/eye/drop Ciclopirox ethanolamine three times daily for 5 days reduced corneal epithelial viral shedding, alleviated blepharitis scores, and decreased latent HSV-1 genome copy numbers in trigeminal ganglia of BALB/c mice with corneal scratch infection of HSV-1 KOS[10].
References:
[1] Abrams BB, Hänel H, Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin Dermatol. 1991 Oct-Dec;9(4):471-7.
[2] Starova A, Aly R. The safety and efficacy of ciclopirox olamine for the treatment of seborrheic dermatitis. Expert Opin Drug Saf. 2005 Mar;4(2):235-9.
[3] Sato E, Kohno M, Nakashima T, Niwano Y. Ciclopirox olamine directly scavenges hydroxyl radical. Int J Dermatol. 2008 Jan;47(1):15-8.
[4] Foti C, Diaferio A, Bonamonte D. Allergic contact dermatitis from ciclopirox olamine. Australas J Dermatol. 2001 May;42(2):145.
[5] Zhou H, Chen H, Luo K, et al. Inhibition of autophagy enhances the sensitivity of ciclopirox olamine in human chronic myelogenous leukemia K562 cells. Int J Med Sci. 2025;22(15):4013-4025.
[6] Du E, Jia X, Li X, et al. Neuroprotective effect of ciclopirox olamine in retinal ischemia/reperfusion injury. BMC Mol Cell Biol. 2024 Oct 9;25:22.
[7] Zhou H, Shang C, Wang M, et al. Ciclopirox Olamine inhibits mTORC1 signaling by activation of AMPK. Biochem Pharmacol. 2016 Sep 15;116:39-50.
[8] Radadiya PS, Thornton MM, Puri RV, et al. Ciclopirox olamine induces ferritinophagy and reduces cyst burden in polycystic kidney disease. JCI Insight. 2021 Mar 30;6(9):e141299.
[9] Xia X, You H, Zhang K, et al. Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases. Adv Sci (Weinh). 2026;13:e75704.
[10] Bernier M, Morrison LA, et al. Topical ciclopirox olamine reduces HSV-1 replication and disease in a mouse corneal infection model. Antiviral Res. 2020 Jan;173:104642.
| Cell experiment [1]: | |
|
Cell lines |
K562 cells (human chronic myelogenous leukemia cell line), OCI-AML2 cells (adult acute myeloid leukemia cell line), HL-60 cells (human promyelocytic leukemia cell line), Jurkat cells (human acute T cell leukemia cell line), RS4-11 cells (human B acute lymphoblastic leukemia cell line), OCI-M2 cells (adult acute myeloid leukemia cell line) |
|
Preparation Method |
K562, OCI-AML2, HL-60, Jurkat, RS4-11 and OCI-M2 cells were maintained in RPMI 1640 or Alpha-MEM supplemented with 10% FBS at 37°C, 5% CO2. Cells were treated with Ciclopirox ethanolamine at 0.064-40μM for 24-48h, followed by MTS assay, Annexin V-FITC/PI staining, JC-1 staining, Western blot, acridine orange staining or transmission electron microscopy to detect viability, apoptosis, mitochondrial membrane potential, autophagy markers (LC3-II, p62), autophagosome formation and AMPK/ULK1/mTORC1 signaling proteins. |
|
Reaction Conditions |
0.064-40μM; 24-48h |
|
Applications |
Ciclopirox ethanolamine decreased viability of K562, OCI-AML2, HL-60, Jurkat, RS4-11 and OCI-M2 cells in a concentration-dependent manner. Ciclopirox ethanolamine induced mitochondrial-mediated apoptosis in OCI-AML2 cells with decreased mitochondrial membrane potential, cleaved caspase-9/PARP and increased Annexin V-positive fraction. Ciclopirox ethanolamine induced little apoptosis in K562 cells even at 20μM. Ciclopirox ethanolamine induced LC3-II conversion and p62 reduction in K562 cells, increased acidic vesicular organelles and autophagosome number, and activated AMPK (p-ACC), ULK1 (p-S555) with suppressed mTORC1 (p-S6K1, p-S6, p-4E-BP1, p-ULK1 S757). Ciclopirox ethanolamine inhibited autophagy in OCI-AML2 cells with reduced LC3-II and elevated p62. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice (WT and NLRP3-/-, male, 10 weeks old for LPS sepsis and DSS colitis models; 6 weeks old for HFD metabolic disorder model) |
|
Preparation Method |
For LPS-induced sepsis, mice were intraperitoneally injected with Ciclopirox ethanolamine (10mg/kg or 20mg/kg) 1h before 20mg/kg LPS i.p.; survival monitored 80h, serum/liver collected at 6h. For DSS-induced colitis, mice received 3% DSS drinking water 6 days then normal water 4 days, with daily i.p. Ciclopirox ethanolamine (20mg/kg) for 10 days. For HFD-induced metabolic disorder, WT and NLRP3-/- mice were fed 60kcal% HFD 12 weeks, then daily i.p. Ciclopirox ethanolamine (2mg/kg) for last 4 weeks, followed by GTT/ITT and tissue harvest. |
|
Dosage form |
2mg/kg-20mg/kg; i.p.; single injection (LPS/sepsis) 2mg/kg-20mg/kg; i.p.; daily injection for 4-10 days (colitis/HFD) |
|
Applications |
Ciclopirox ethanolamine improved survival of LPS-challenged mice, reduced serum ALT and AST, attenuated liver pathological injury, and lowered caspase-1 cleavage and IL-1β secretion in liver. Ciclopirox ethanolamine reduced DSS-induced body weight loss and disease activity index, prevented colon length shortening, mitigated crypt disappearance and inflammatory cell influx in colon, and suppressed caspase-1 cleavage and IL-1β secretion in colon. Ciclopirox ethanolamine reduced HFD-induced weight gain and food intake in WT but not NLRP3-/- mice, decreased serum ALT and AST, improved insulin sensitivity, ameliorated hepatic steatosis and intracellular lipid accumulation, and inhibited caspase-1 cleavage and IL-1β secretion in liver of WT but not NLRP3-/- mice. |
References: [1] Mallmann MP, Oliveira MS. Beta-caryophyllene in psychiatric and neurological diseases: Role of blood-brain barrier. Vitam Horm. 2024;126:125-168. [2] Xia X, You H, Zhang K, et al. Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases. Adv Sci (Weinh). 2026;13:e75704. | |
| Cas No. | 41621-49-2 | SDF | |
| Chemical Name | 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one | ||
| Canonical SMILES | CC1=CC(=O)N(C(=C1)C2CCCCC2)O.C(CO)N | ||
| Formula | C12H17NO2.C2H7NO | M.Wt | 268.35 |
| Solubility | Insoluble in water | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7265 mL | 18.6324 mL | 37.2648 mL |
| 5 mM | 745.3 μL | 3.7265 mL | 7.453 mL |
| 10 mM | 372.6 μL | 1.8632 mL | 3.7265 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)